Microbiome Invest 2018 | Kisaco Research
Novotel London West, London, UK
23 May, 2018
Download Agenda
Speakers
Register

Why Attend

The Microbiome Invest Congress 2018 is dedicated to showcasing the most innovative emerging companies and academics with commercially viable research that manipulates the microbiome. Active investors, and multi-national nutrition and pharmaceutical companies will also share their knowledge and perspectives on commercialisation and discuss the most cutting-edge products and research in the microbiome space. 

“The human microbiome market is expected to reach USD 658 Million by 2023 from USD 294 Million in 2019 growing at a CAGR of 22.3% during the forecast period (2019–2023)” Human Microbiome Market Industry Report – Markets and Markets

100+
Delegates
50:50
Ratio of Academics - Industry
8+
Microbiome Niches Covered
16+
Industry Leading Speakers
4+
Hours of Dedicated Networking

'Pitch Your Microbes' Finalists

Author:

Dominik Burziwoda

CEO
Perfood GmbH

Prior to founding MillionFriends Dominik worked as Head of Operations at the German E-Commerce company Springlane. The company scaled from 8 to >100 people within 3 years. He started his career as an Investment Banker with Lincoln International and worked at Innogy on M&A and financing transactions of renewable energy plant across Europe. He graduated with an LL.M. from University of Munster, with a Master in Finance from IE Business School and holds a BSc in Business from Rotterdam School of Management. He is a passionate snowboarder and healthcare tech enthusiast.

Author:

Evelina Vågesjö, PhD MBA

CEO
Ilya Pharma

Co-founder of and developed the concept during PhD 2011-2016, is now CEO and heading the drug and business development in Ilya Pharma. Also BSc in Management Accounting and finished an MBA 2018. Raised >4.3 M€ in grant funding to the project, lead the first private share issue in 2017 and designed stock option programs for key employees.  

Author:

Kristofer Cook

CEO & Co-Founder
Carbiotix

Kristofer received his master’s degree from Lund University, Sweden, and M.B.A. from Solvay Business School, Belgium. Over the past 10 years, he co-founded four different biotechnology spin-off companies in the areas of renewable energy, green chemistry, bio-plastics and food ingredients. In addition to holding several board positions, Kristofer is currently CEO of Carbiotix AB, an award-winning consumer biotechnology company focused on simple, affordable and effective gut health solutions and their impact on the microbiome.  

Author:

Grégory Lambert

CEO
TargEDys SA

Grégory Lambert’s career has been split between biotech and pharma as VP of R&D and CSO in companies such as Novagali Pharma (now Santen) and Septodont. His responsibilities have included innovation, CMC, pre-clinical and clinical development in both Europe and North America. Grégory also has experience managing IP, business development and general management.  He is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he has driven the development of several pharmaceutical products from the laboratory through to market authorisation. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations, so far has raised over 10M€ in a mixture of grant and VC funding and begins human clinical trials this year.

Author:

Mats Wallstrom

CEO
Lavivo

Mats is an engineer by education with a special interest in what makes the body perform. He has dedicated years of development of the Qualvivo bacterial boxed-system technology.

Mats is motivated to grow a company and to introduce products on the international market. He identified a window of opportunity to develop the power of bacteria and combined partnering expertise in biotechnology with an engineering approach to develop Qualvivo.

Author:

Richard Andrews

CEO
Azitra

Mr.  Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrumental in translating research and academic discoveries into product development and advanced clinical programs, building alliances and partnerships and organizing operational teams. Financing processes led by Mr. Andrews have secured over $130M in equity funding for new ventures. His work has been primarily focused on skin disease, pneumonia, infant hypoxic ischemia and kidney failure. Early in his career, Mr. Andrews led the commercialization of several natural cell systems to prevent disease on fruits and vegetables and launched several DNA diagnostic tests for periodontal disease. Mr. Andrews received graduate degrees in physical biochemistry (MS), and technology management (SM) from Purdue University, and the Massachusetts Institute of Technology, respectively. He also has an undergraduate degree in Chemistry (BS) from Hobart College.

Author:

Gregory McKenzie, Ph.D.

Vice President of Research and CSO
ConsortiaTX

Gregory McKenzie, Ph.D., Vice President and Chief Scientific Officer, has over ten years of experience developing microbial-based products and leading discovery and development teams. Greg was formerly Senior Principal Scientist at Seres Therapeutics where he was a key senior member of the teams that brought the live biotherapeutics SER-109, SER-262, and SER-287 from discovery through proof-of-concept in animals to clinical stage programs. 

Author:

Dr Soren Krogsgaard Thomsen

CEO
BioMe Oxford

Dr Soren Krogsgaard Thomsen is co-founder and CEO of the UK-based start-up company BioMe Oxford. Trained in medical genetics at the Universities of Oxford and Cambridge, Soren has a background in both academic and industrial life sciences research. His publication record spans work on the genetics of complex diseases and academic entrepreneurship. Since co-founding BioMe Oxford, he has successfully led the company to raising pre-seed investment, winning a number of international business competitions along the way (incl. Imagine IF and Idea Idol). Soren dreams of enabling a revolution in precision medicine through population-wide studies of our second genome within. 

Author:

Dr Luis Gosalbez

Director of Business Development
OptiBiotix Ltd

Luis is the Director of Business Development at OptiBiotix Health in the UK. Previously, he held different positions in the biotechnology industry and in pharmaceutical consulting in Spain and Germany. His scientific career was developed between Universidad Complutense de Madrid, Centro de Biología Molecular Severo Ochoa-CSIC (both in Spain) and the Korea Advanced Institute of Science and Technology (KAIST, South Korea). His research was always focused on microbiology, the human microbiome and on the development of antimicrobials and antivirals. He received his BSc and MSc in Biotechnology from Universidad Complutense de Madrid, his PhD in Life Sciences from the Catholic University of San Antonio (Spain) and a Master’s in Bioscience Enterprise from the University of Cambridge in the UK.

The Speakers

 

Adrian Ferrero

CO-founder and CEO
Biome Makers Inc

Adrian Ferrero

CO-founder and CEO
Biome Makers Inc

Adrian Ferrero

CO-founder and CEO
Biome Makers Inc
 

Andrew Morgan

Chair
KTN Microbiome Innovation Network

Dr Andrew Morgan is Chair of the UK’s KTN Microbiome Special Interest Group and has close to 40 years’ experience in health & nutrition research & innovation related to microbe-host interactions including human, animal and plant. He held the role of Chief Scientist to DuPont’s Nutrition & Health and legacy Danisco business (2008-2019) and was a DuPont Fellow. Having joined the company as a member of the pioneering FFI animal nutrition enzyme team, he then went on to play a key role in helping build DuPont’s microbiome platform. Andrew retired from DuPont at the end of 2019.

Andrew Morgan

Chair
KTN Microbiome Innovation Network

Andrew Morgan

Chair
KTN Microbiome Innovation Network

Dr Andrew Morgan is Chair of the UK’s KTN Microbiome Special Interest Group and has close to 40 years’ experience in health & nutrition research & innovation related to microbe-host interactions including human, animal and plant. He held the role of Chief Scientist to DuPont’s Nutrition & Health and legacy Danisco business (2008-2019) and was a DuPont Fellow. Having joined the company as a member of the pioneering FFI animal nutrition enzyme team, he then went on to play a key role in helping build DuPont’s microbiome platform. Andrew retired from DuPont at the end of 2019.

 

Marie Drago

Founder
Gallinée

Marie Drago is a French Doctor in Pharmacy and a member of the French Society of Cosmetic Science, with over 15 years’ experience working for successful and innovative skincare brands. After discovering how a prebiotic and probiotic diet could improve the symptoms of the gluten intolerance that had been plaguing her life for years, Marie got a Eureka moment: What if we applied the same science to skin?

Marie Drago

Founder
Gallinée

Marie Drago

Founder
Gallinée

Marie Drago is a French Doctor in Pharmacy and a member of the French Society of Cosmetic Science, with over 15 years’ experience working for successful and innovative skincare brands. After discovering how a prebiotic and probiotic diet could improve the symptoms of the gluten intolerance that had been plaguing her life for years, Marie got a Eureka moment: What if we applied the same science to skin?

Marie’s thesis on the microbiome and the enormous benefits of harnessing helpful bacteria gave her the vision and the know-how to create Gallinée’s formulations. Thanks to her pharmacy background and her beauty experience, Marie designed formulas like no other, and patented the triple biotic complex that you can now find in Gallinée’s products.

 

Artem Khlebinkov

Director of Strategist Partnerships
Danone Nutrica Research

Artem Khlebinkov

Director of Strategist Partnerships
Danone Nutrica Research

Artem Khlebinkov

Director of Strategist Partnerships
Danone Nutrica Research
 

Isabelle De Cremoux

CEO
Seventure Partners

Isabelle De Cremoux

CEO
Seventure Partners

Isabelle De Cremoux

CEO
Seventure Partners
 

David Berry

General Partner
Flagship Ventures

David Berry

General Partner
Flagship Ventures

David Berry

General Partner
Flagship Ventures
 

Bram Vanparys

Investment Director
Merck Ventures

Bram Vanparys

Investment Director
Merck Ventures

Bram Vanparys

Investment Director
Merck Ventures
 

Derek Butler

CEO
MyMicroZoo

Derek Butler

CEO
MyMicroZoo

Derek Butler

CEO
MyMicroZoo
 

Jim Weston

Vice President and Head of Regulatory Affairs
Seres Therapeutics

Jim Weston

Vice President and Head of Regulatory Affairs
Seres Therapeutics

Jim Weston

Vice President and Head of Regulatory Affairs
Seres Therapeutics
 

Dr David Cook

Chief Scientific Officer
Seres

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr.

Dr David Cook

Chief Scientific Officer
Seres

Dr David Cook

Chief Scientific Officer
Seres

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. (“Seres”). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.

 

John Hambour

Director of Research Beyond Borders
Boehringer Ingelheim

John Hambour

Director of Research Beyond Borders
Boehringer Ingelheim

John Hambour

Director of Research Beyond Borders
Boehringer Ingelheim
 

Luc Sterkman

CEO
Caelus Health B.V.

Luc Sterkman

CEO
Caelus Health B.V.

Luc Sterkman

CEO
Caelus Health B.V.
 

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities.

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos

Chief Executive Officer
Microbiotica Ltd.

Mike Romanos is a co-founder and Chief Executive of Microbiotica. He has 30 years’ experience in the biotech and pharma industry and previously co-founded Crescendo Biologics which he built and led as CEO and CSO, developing a leading antibody fragment discovery platform and pipeline in oncology and inflammation. Prior to that he held global VP roles in GlaxoSmithKline R&D over 10 years, during which time he formed and led major transnational divisions which helped shape the company’s discovery platforms and pipelines across therapeutic areas and modalities. In his last role he led a transnational group of 300 staff providing genomics, target and biomarker discovery, and platform biology for R&D. Mike is highly experienced in biotech translation and commercialisation, currently serving as a Non-Exec Director of the life-sciences charity LifeArc, and previously as Translational Adviser in Biomedicine at Imperial College, Venture Partner to UK Innovation and Science Seed Fund, and committee member on the MRC’s Developmental Pathway Funding Scheme for translational academic research. Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and is a Fellow of the Royal Society of Biology.

 

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx

Assaf Oron

Chief Business Officer
Biomx
 

Xavier Duportet

CEO
Eligo Biosciences

Xavier Duportet

CEO
Eligo Biosciences

Xavier Duportet

CEO
Eligo Biosciences

The Agenda

Event Agenda

Pitch Your Microbes

Central to MICROBIOME INVEST is ‘Pitch Your Microbes’, a platform for 12 of the most exciting emerging companies in microbiome to pitch their innovative ideas to a room full of potential advisors, investors and partners. Our esteemed selection committee will handpick these final
12 presenting companies from the list of all applicants.

To apply, you should meet one of the following entry criteria:

- An academic with a desire to develop and commercialise an innovative idea or piece of research that will benefit patients.
- A recent spin-out from an academic institution looking for financial investment, partnerships and advice.
- A biotech company at the pre-revenue or post-revenue stage, looking for financial investment, partnerships, licencing deals and advice.

CLICK HERE TO APPLY

DEADLINE: 6th APRIL 2018

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Media Partners

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Academics, Biotech companies (under 3 years old), and Investors
£599 +VAT
Standard Pricing
Main Conference
One-to-One Meeting Scheduler
Post-Show Access to Presentations
Poster Sessions
Complimentary Articles and Content
Pharmaceutical, Nutrition & Biotech companies (over 3 years old)
£1,599 + VAT
Standard Pricing
Main Conference
One-to-One Meeting Scheduler
Post-Show Access to Presentations
Poster Sessions
Complimentary Articles and Content
Vendors (including Investment bankers, Lawyers, Consultants)
£1,899 + VAT
Standard Pricing
Main Conference
One-to-One Meeting Scheduler
Post-Show Access to Presentations
Poster Sessions
Complimentary Articles and Content
Poster Session (FREE for attendees (£50 for Non-Attendees)
£50 + VAT
Standard Pricing
Poster Session
Preparing registration...

Book a Team to Save More!

Industry Rates Only: Team discounts cannot be combined with any other discount or offer

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

 

Venue

Novotel London West, 1, Shortlands, W6 8DR, London

Room rate: £139 includes VAT and English breakfast. 

To book a room telephone reservations on + 44 (0) 208 741 1555  or

Email: [email protected]

Always quote:  KISACO220518

Book by 25 April 2018 

 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.